SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.200
+0.130 (4.23%)
Oct 28, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
86
Market Cap
291.16M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Clinuvel Pharmaceuticals | 65.05M |
| Bicycle Therapeutics | 61.21M |
| Q32 Bio | 53.74M |
| Abeona Therapeutics | 25.52M |
| Lineage Cell Therapeutics | 13.08M |
| Fate Therapeutics | 6.49M |
| Vicore Pharma Holding AB | 412.09K |
SABS News
- 8 days ago - SAB Biotherapeutics Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 14 days ago - SAB BIO to Participate in Chardan 10th Annual Healthcare Conference - GlobeNewsWire
- 15 days ago - SAB Biotherapeutics granted Fast Track designation for SAB-142 - TheFly
- 15 days ago - SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes - GlobeNewsWire
- 18 days ago - SAB Biotherapeutics Slides: Corporate presentation - Filings
- 27 days ago - SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress - GlobeNewsWire
- 4 weeks ago - SAB Biotherapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes - GlobeNewsWire